Novo Nordisk's DegludecPlus filing ups ante in Japan basal insulin market
This article was originally published in Scrip
Executive Summary
Novo Nordisk has filed for the approval in Japan of its combination product DegludecPlus (70% insulin degludec plus 30% fast-acting insulin aspart (NovoRapid)), for the treatment of both type 1 and 2 diabetes.